Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 8-K (Current Report)
Date of Report: August 16, 2021
Reporting Period: Three months ended June 30, 2021
Context: The filing announces the company's results of operations and financial condition for the second quarter of 2021 and provides a business update. The detailed financial data is contained in a press release (Exhibit 99.1) incorporated by reference.
Key Financial Metrics
The provided text serves as a cover document referencing a press release for specific data. Consequently, the filing text itself does not provide clear values for the following metrics:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Investors must refer to the attached Exhibit 99.1 (Press Release) for these specific figures.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. It directs readers to the press release for the announcement of results and the business update.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains forward-looking statements regarding future financial performance and business updates. Management notes that actual results could differ significantly from expectations due to risks and uncertainties.
Risk Factors: The document references the "Risk Factors" section in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and subsequent SEC filings for a comprehensive list of risks.
Legal Status: Information in Item 2.02 is furnished, not filed, and will not be incorporated by reference into registration statements unless specifically identified.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2021 revenue, cash burn, and liquidity figures.
- Verify the company's cash runway and funding status as of June 30, 2021.
- Consult the 2020 Form 10-K for detailed risk factors affecting the biotechnology sector and the company's pipeline.
- Confirm the status of clinical trials or business development activities mentioned in the business update.